We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Chided Over Lack of Transparency in Pediatric Trials Waiver Process
EMA Chided Over Lack of Transparency in Pediatric Trials Waiver Process
June 7, 2012
The EU Ombudsman June 4 criticized the European Medicines Agency’s (EMA) lack of transparency and guidelines for deciding when to require drugmakers to carry out pediatric clinical trials.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor